TABLE 1.

Animals included in the study

SIV groupAnimal no.VLaPrevious treatment (wks after infection)b
SIVLO883<2,000ART (15-40)
884<2,000ART (15-40)
207<2,000ART (15-40)
916<2,000ART (15-40); ALVAC-SIV (24, 30, 36); IL-15 (24, 30, 36)
299<2,000ART (15-40); IL-15 (24, 30, 36)
8782,092ART (15-40); ALVAC-SIV (24, 30, 36)
879<2,000ART (15-40); ALVAC-SIV (24, 30, 36)
221<2,000Preventive MVA-SIV and ADENO-SIV vaccination
SIVHI9114,650,525ART (15-40); ALVAC-SIV (24, 30, 36); IL-7 (24, 30)
89028,016ART (15-40)
20214,467ART (15-40)
54740,075None
173380,647None
55210,388,308None
305338,699None
930278,509ART (15-40); ALVAC-SIV (24, 30, 36); IL-15 (24, 30, 36)
  • a VL, plasma viral level at euthanasia.

  • b ART, all animals had not received antiretroviral therapy (ART) for at least 52 weeks before euthanasia. The “-SIV” suffix indicates “SIV vaccinated.” IL-15, IL-15 given subcutaneously twice a week for three consecutive weeks at a dose of 10 μg/kg for a total of six doses per cycle. IL-7, IL-7 given subcutaneously every 3 days starting 2 weeks before immunization and maintained for 1 week thereafter at 100 μg/kg for a total of eight doses per cycle.